Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DA97XT
|
|||
| Drug Name |
TransCon CNP
|
|||
| Synonyms |
ACP-015
Click to Show/Hide
|
|||
| Indication | Achondroplasia [ICD-11: LD24.00; ICD-10: Q77.4; ICD-9: 756.4] | Phase 2/3 | [1] | |
| Company |
Ascendis Pharma North Brunswick, NJ
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05598320) A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension Period. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.